236. Pseudohypoparathyroidism
6 clinical trials,   4 drugs   (DrugBank: 2 drugs),   20 drug target genes,   28 drug target pathways

Searched query = "Pseudohypoparathyroidism", "PHP", "PHP1a", "PHP1b", "PHP1c", "PHP2"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04551170
(ClinicalTrials.gov)
July 13, 20209/9/2020Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years OldPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary Osteodystrophy;Pseudohypoparathyroidism Type 1aDrug: Theophylline;Drug: PlaceboVanderbilt University Medical CenterNULLRecruiting2 Years12 YearsAll34Phase 2United States
2NCT04240821
(ClinicalTrials.gov)
May 22, 202021/1/2020Theophylline for Treatment of PseudohypoparathyroidismOpen-Label Extension Study of Theophylline for Treatment of PseudohypoparathyroidismPseudohypoparathyroidism;Pseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: Theophylline ERAshley ShoemakerNULLEnrolling by invitation2 Years99 YearsAll34Phase 2United States
3NCT03718403
(ClinicalTrials.gov)
April 10, 20198/9/2017Effect of Theophylline in PseudohypoparathyroidismEffect of Theophylline in PseudohypoparathyroidismPHP Ia;PHP IB;Php1CDrug: TheophyllineMassachusetts General HospitalNULLNot yet recruiting5 Years21 YearsAll40Phase 4NULL
4NCT03029429
(ClinicalTrials.gov)
September 1, 201818/1/2017Theophylline Treatment for PseudohypoparathyroidismPhase 2 Study of Theophylline Treatment for PseudohypoparathyroidismPseudohypoparathyroidism;Albright Hereditary OsteodystrophyDrug: Theophylline;Drug: PlacebosVanderbilt University Medical CenterHarvard UniversityRecruiting13 Years99 YearsAll34Phase 2United States
5NCT02463409
(ClinicalTrials.gov)
June 201520/5/2015Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1aPseudohypoparathyroidism Type 1a;Albright Hereditary OsteodystrophyDrug: TheophyllineVanderbilt University Medical CenterMassachusetts General HospitalCompleted10 Years21 YearsAll6Phase 2United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00497484
(ClinicalTrials.gov)
February 19955/7/2007Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)Pseudohypoparathyroidism;Growth Hormone Deficiency, DwarfismDrug: recombinant human somatotropinUniversity of MilanEli Lilly and CompanyActive, not recruiting1 Year18 YearsBothN/AItaly